Lexaria's DehydraTECH semaglutide outperforms Rybelsus in human pilot study

Lexaria Bioscience Corp.

DehydraTECH semaglutide showed 43% higher peak blood levels vs Rybelsus; levels higher at all 19 time points.
Blood glucose reduced by 5.01% at 24 hours vs baseline for DehydraTECH; Rybelsus group unchanged.
No moderate nausea or diarrhea reported with DehydraTECH; Rybelsus caused both side effects.
Lexaria preparing additional human and animal studies on expedited basis for GLP-1 drugs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.